Android app on Google Play

NuPathe (PATH) Announces FDA Approval of Zecuity; Shares Surge

January 17, 2013 7:33 PM EST Send to a Friend
NuPathe Inc. (NASDAQ: PATH) ramped 18% after-hours Thursday after the company announced FDA approval of Zecuity for the acute treatment of migraine with or without aura in adults.

Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin. Zecuity provides relief of both migraine headache pain and migraine-related nausea (MRN).

"The approval of Zecuity represents a major milestone for NuPathe and migraine sufferers," said Armando Anido, CEO of NuPathe. "As the first and only FDA-approved migraine patch, we believe Zecuity will be a game-changing treatment option for millions of migraine patients, especially those with migraine-related nausea. We thank the patients and physicians who participated in our clinical trials as well as our employees for their support throughout the development of Zecuity. We now intensify our focus to securing commercial partners and preparing for the launch of Zecuity expected in the fourth quarter of this year."




You May Also Be Interested In


Related Categories

FDA, Hot FDA News, Trading Halts

Add Your Comment